Phillip Bowman, APRN
Nurse Practitioner · Salt Lake City, UTNPI 1619231701
Payments from drug & device makers
Across 838 payments — averaging $21.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Eli Lilly$5K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$934
- Bristol Myers Squibb$564
- QOL Medical, LLC$562
- plus $5K from 29 others
Across 1 payment — averaging $14,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$14K
What the payments were for
- Food & beverage$12,96499%
- Education$1101%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 317 | $4,869 |
| Eli Lilly | 1 | $4,544 |
| Takeda Pharmaceuticals U.S.A., Inc. | 59 | $1,228 |
| Johnson & Johnson | 68 | $934 |
| Bristol Myers Squibb | 51 | $564 |
| QOL Medical, LLC | 34 | $562 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $520 |
| Nestle Healthcare Nutrition Inc. | 32 | $510 |
| Pfizer | 63 | $490 |
| Ardelyx, Inc. | 23 | $429 |
| Aimmune Therapeutics, Inc. | 23 | $398 |
| Phathom Pharmaceuticals, Inc. | 22 | $378 |
| Gilead | 17 | $370 |
| Sanofi | 12 | $260 |
| Regeneron Healthcare Solutions, Inc. | 14 | $249 |
| Intuitive Surgical | 2 | $221 |
| E.r. Squibb & Sons, L.L.C. | 2 | $219 |
| Redhill Biopharma Inc. | 14 | $186 |
| Madrigal Pharmaceuticals | 6 | $148 |
| Organon | 7 | $101 |
| Merck | 3 | $66 |
| Braintree Laboratories, Inc. | 3 | $63 |
| Novo Nordisk | 3 | $44 |
| Ferring Pharmaceuticals Inc. | 3 | $43 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Ipsen Biopharmaceuticals, Inc | 1 | $27 |
| Intercept Pharmaceuticals, Inc. | 1 | $26 |
| Enterra Medical, Inc. | 1 | $24 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $20 |
| Biogen | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| Lilly USA, LLC | 1 | $17 |
| Evoke Pharma, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Lucid Diagnostics Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Entyvio$241
- Da Vinci Surgical System$221
- ZEPOSIA$127
- Skyrizi$124
- VOQUEZNA$112
How this compares
$17,618 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 15 | $98,484 |
| CreonLipase/Protease/Amylase | 20 | $47,375 |
| LinzessLinaclotide | 38 | $39,697 |
| Mesalamine | 21 | $9,879 |
| CholestyramineCholestyramine (With Sugar) | 59 | $3,829 |
| Dexlansoprazole DrDexlansoprazole | 11 | $3,396 |
| Famotidine | 123 | $2,488 |
| Omeprazole | 87 | $1,656 |
| Pantoprazole Sodium | 105 | $1,280 |
| Sucralfate | 22 | $679 |
| Dicyclomine Hcl | 20 | $580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $398 | $98,48415 claims |
| AbbVieCreon, Linzess | $4,869 | $87,07258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Salt Lake City
- Julia BattenSalt Lake City$223K
- Merin KinikiniSalt Lake City$19K
- Dana ShawSalt Lake City$10K
- Samantha AbertonSalt Lake City$10K
- Jennifer BushSalt Lake City$7K
- Stacy ParrySalt Lake City$6K
- Krystal BischoffSalt Lake City$5K
- Jennifer UrchSalt Lake City$5K
- Millie DorseySalt Lake City$5K
- Diane RussellSalt Lake City$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.